{"id":"bbc654e5-e934-5e8d-8ef0-371111f679b0","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-uncontrolled-survival-figures","predicate":"modulates","statement":"Kaplan-Meier analysis showed a 21-month median overall survival with 41.7% of patients alive at 2 years and 25% at 3 and 4 years, and median progression-free survival from diagnosis was 13.1 months for 17 patients taking more than one month of mebendazole against 9.2 months for 7 patients who received less than one month, with the authors concluding that further studies are needed to determine efficacy in malignant glioma.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"3d603500-a8cf-51ca-8ff1-515b0df9bf17","mechanism_event_label":"Patients who stayed on it longer did better, but there was no control group and staying on a drug longer is itself a sign of doing well.","subject":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"object":{"id":"ad94cfea-9646-5b72-9c22-9faa10195be5","slug":"progression-free-survival","display_name":"Progression-free survival in high-grade glioma","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"3d603500-a8cf-51ca-8ff1-515b0df9bf17","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-uncontrolled-survival-figures-event","event_type":"observed_intervention","label":"Patients who stayed on it longer did better, but there was no control group and staying on a drug longer is itself a sign of doing well.","description":"Kaplan-Meier analysis showed a 21-month median overall survival with 41.7% of patients alive at 2 years and 25% at 3 and 4 years, and median progression-free survival from diagnosis was 13.1 months for 17 patients taking more than one month of mebendazole against 9.2 months for 7 patients who received less than one month, with the authors concluding that further studies are needed to determine efficacy in malignant glioma.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"85eea0d4-b97f-5850-b259-734a9f44e65c","slug":"temozolomide","display_name":"Temozolomide","entity_type_key":"drug"},"role":"co_administered_drug","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"ad94cfea-9646-5b72-9c22-9faa10195be5","slug":"progression-free-survival","display_name":"Progression-free survival in high-grade glioma","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/mebendazole-research/33506200.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"ab5f2c1d14ccb7fa9f690201326bdbfcab3e07758bc78b76ff9adec2ca774ec6\", \"start_char\": 0, \"end_char\": 1712, \"text_sha256\": \"ab5f2c1d14ccb7fa9f690201326bdbfcab3e07758bc78b76ff9adec2ca774ec6\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Single-centre dose-escalation and safety study in 24 patients with newly diagnosed high-grade glioma","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Oral mebendazole at 25, 50, 100 and 200 milligrams per kilogram per day with adjuvant temozolomide, with trough plasma levels at 4, 8 and 16 weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The only human oncology record here. It is a single-arm dose-escalation and safety study without a control group, so the survival figures cannot be read as efficacy.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.","comparator":null,"unit":null,"notes":"","entity":{"slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Patients who stayed on it longer did better, but there was no control group and staying on a drug longer is itself a sign of doing well.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[mbz-p33506200] Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33506200/ DOI: 10.1093/noajnl/vdaa154","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Brain","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"597389bb-ad46-5b03-bd62-0164728c69c2","evidence_kind":"source_excerpt","locator":"Lines 589-600","start_line":589,"end_line":600,"excerpt":"### mbz-uncontrolled-survival-figures\nKaplan-Meier analysis showed a 21-month median overall survival with 41.7% of patients alive at 2 years and 25% at 3 and 4 years, and median progression-free survival from diagnosis was 13.1 months for 17 patients taking more than one month of mebendazole against 9.2 months for 7 patients who received less than one month, with the authors concluding that further studies are needed to determine efficacy in malignant glioma.\nCondition category: normal\nnutrient_topic: Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.\nplain_language: Patients who stayed on it longer did better, but there was no control group and staying on a drug longer is itself a sign of doing well.\norganism: Human\ntissue_or_cell_type: Brain\nexperimental_model: Single-centre dose-escalation and safety study in 24 patients with newly diagnosed high-grade glioma\nlimitations: The only human oncology record here. It is a single-arm dose-escalation and safety study without a control group, so the survival figures cannot be read as efficacy.\nexposure: Oral mebendazole at 25, 50, 100 and 200 milligrams per kilogram per day with adjuvant temozolomide, with trough plasma levels at 4, 8 and 16 weeks\nevidence_span: {\"source_cache\": \"artifacts/mebendazole-research/33506200.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"ab5f2c1d14ccb7fa9f690201326bdbfcab3e07758bc78b76ff9adec2ca774ec6\", \"start_char\": 0, \"end_char\": 1712, \"text_sha256\": \"ab5f2c1d14ccb7fa9f690201326bdbfcab3e07758bc78b76ff9adec2ca774ec6\"}\n[mbz-p33506200] Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33506200/ DOI: 10.1093/noajnl/vdaa154","model_system":"Single-centre dose-escalation and safety study in 24 patients with newly diagnosed high-grade glioma","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [mbz-p33506200] Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33506200/ DOI: 10.1093/noajnl/vdaa154","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"06104773-03d0-5e5c-b9da-eb484e7be657","stable_key":"import-f2ec2007-88ff-5a96-a73b-8b5085e9cea9","title":"Mebendazole: the tubulin it binds, why that is selective, the crystal form that decides whether any of it works, and the off-target that became an oncology programme (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"58b652636677e5033fd1dd555744485fcef18f21a97dcf68723fe072b656f413","revision_id":"a2cd9c22-0549-52ca-a653-8a0c2362ec85","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}